Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Andrew Goodearl
Programmed Death-1 Targeting Can Promote Allograft Survival
Journal of Immunology
Allergy
Immunology
Related publications
Programmed Cell Death-1/Programmed Death-Ligand 1 Blockade Improves Survival of Animals With Sepsis: A Systematic Review and Meta-Analysis
BioMed Research International
Immunology
Molecular Biology
Biochemistry
Microbiology
Medicine
Genetics
Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Clinical Cancer Research
Cancer Research
Oncology
Variations in DNA Methylation of Interferon Gamma and Programmed Death 1 in Allograft Rejection After Kidney Transplantation
Clinical Epigenetics
Genetics
Developmental Biology
Molecular Biology
Targeting the Cell Death-Survival Equation
Clinical Cancer Research
Cancer Research
Oncology
Oxidized LDL Can Promote Human Monocyte Survival
Arteriosclerosis, Thrombosis, and Vascular Biology
Cardiovascular Medicine
Cardiology
Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
Frontiers in Oncology
Cancer Research
Oncology
“Programmed Cell Death: A Process of Death for Survival” – How Far Terminology Pertinent for Cell Death in Unicellular Organisms
Journal of Cell Death
Biochemistry
Cell Biology
Recurrent Pneumonitis Induced by Atezolizumab (Anti–Programmed Death Ligand 1) in NSCLC Patients Who Previously Experienced Anti-Programmed Death 1 Immunotherapy-Related Pneumonitis
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
JAMA Dermatology
Dermatology
Medicine
